Prevenar13 Post Market Surveillance

CompletedOBSERVATIONAL
Enrollment

649

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Healthy
Interventions
BIOLOGICAL

13-valent pneumococcal vaccine

0.5mL IM (Intramuscular administration) as per recommended schedule

Trial Locations (18)

701847

Jaeil Alliance Pediatrics Clinic, Daegu

702886

Teun Teun Pediatric Clinic, Daegu

220-956

Choi's Pediatric Clinic, Wŏnju

447-804

Seoul Children's Hospital, Osan

463-821

Bundang Pediatric Clinic, Seongnam-si

443-471

Teun Teun Pediatric clinic, Suwon

482-050

Namujungwon Women's Hospital, Yangju

448-508

Yonsei Pediatric Clinic, Yongin-si

602-739

Busan National University Hospital, Busan

302-799

Eulji University Hospital, Daejeon

425-707

Korea University Ansan Hospital, Gyeonggi-do

463-712

Cha Bundang Medical Center, Cha University, Gyeonggi-do

400-711

Inha University Hospital, Incheon

402-852

Lee Ha Young Pediatrics, Incheon

138-736

Asan Medical Center, Seoul

139-711

Eulji Medical Center, Seoul

613-806

JaMo Women's Hospital, Suyeong-gu

682-714

Ulsan University Hospital, Ulsan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01509105 - Prevenar13 Post Market Surveillance | Biotech Hunter | Biotech Hunter